Consolidated Statements of Income (Loss) - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Net revenues	$ 3,982	$ 4,357
Cost of sales	2,104	2,294
Gross profit	1,878	2,063
Research and development expenses	254	221
Selling and marketing expenses	585	613
General and administrative expenses	290	304
Intangible assets impairments	79	649
Other assets impairments, restructuring and other items	137	121
Legal settlements and loss contingencies	104	(25)
Other income	(5)	(13)
Operating (loss) income	434	191
Financial expenses, net	290	224
Income (loss) before income taxes	144	(33)
Income taxes (benefit)	62	(59)
Share in (profits) losses of associated companies, net	(3)	1
Net income (loss)	84	25
Net income (loss) attributable to non-controlling interests	7	(44)
Net income (loss) attributable to Teva	$ 77	$ 69
Earnings (loss) per share attributable to ordinary shareholders:
Basic	$ 0.07	$ 0.06
Diluted	$ 0.07	$ 0.06
Weighted average number of shares (in millions):
Basic	1,099	1,093
Diluted	1,107	1,096